TY - JOUR
T1 - Overcoming Chemotherapy Resistance in SCLC
AU - Herzog, Brett H.
AU - Devarakonda, Siddhartha
AU - Govindan, Ramaswamy
N1 - Publisher Copyright:
© 2021
PY - 2021/12
Y1 - 2021/12
N2 - SCLC is an aggressive form of lung cancer with a very poor prognosis. Although SCLC initially responds very well to platinum-based chemotherapy, it eventually recurs and at recurrence is nearly universally resistant to therapy. In light of the recent advances in understanding regarding the biology of SCLC, we review findings related to SCLC chemotherapy resistance. We discuss the potential clinical implications of recent preclinical discoveries in altered signaling pathways, transcriptional landscapes, metabolic vulnerabilities, and the tumor microenvironment.
AB - SCLC is an aggressive form of lung cancer with a very poor prognosis. Although SCLC initially responds very well to platinum-based chemotherapy, it eventually recurs and at recurrence is nearly universally resistant to therapy. In light of the recent advances in understanding regarding the biology of SCLC, we review findings related to SCLC chemotherapy resistance. We discuss the potential clinical implications of recent preclinical discoveries in altered signaling pathways, transcriptional landscapes, metabolic vulnerabilities, and the tumor microenvironment.
KW - Chemoresistance
KW - Chemotherapy
KW - Resistance
KW - SCLC
KW - Small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85113289563&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2021.07.018
DO - 10.1016/j.jtho.2021.07.018
M3 - Review article
C2 - 34358725
AN - SCOPUS:85113289563
SN - 1556-0864
VL - 16
SP - 2002
EP - 2015
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 12
ER -